Shanghai, China – YS Biopharma Co., Ltd. hosted its Q3 2024 Earnings Conference Call on April 19, 2024, at 8:00 AM ET. The company’s top executives, including Alyssa Li, Director of Investor Relations, David Shao, President & Chief Executive Officer, Zenaida Mojares, Chief Medical Officer, and Brenda Wu, Chief Financial Officer, provided insights into the company’s performance for the first nine months of Fiscal Year 2024.

During the call, Dr. David Shao highlighted the company’s operational improvements, specifically in addressing inventory issues at the YSJA rabies vaccine manufacturing facility. These enhancements led to a return to normal vaccine production and an improvement in inventory levels, positioning the company as a leading rabies vaccine producer in China.

Despite a year-over-year decline in revenue and a net loss for the period, YS Biopharma remains optimistic about future growth prospects. The company expects double-digit year-over-year growth in product sales for the three-month period ending on March 31, 2024, and aims to increase product sales in fiscal year 2025.

The management team also discussed strategic initiatives aimed at enhancing internal controls, governance, and operational efficiency. This includes optimizing the product pipeline, implementing cost controls, and expanding production distribution capabilities to meet the demand for the YSJA rabies vaccine.

Dr. Zenaida Mojares provided key updates on the development of the PIKA rabies vaccine and PIKA HBV 002 vaccine, highlighting positive results from clinical trials and progress towards commercialization. These vaccines offer promising advancements in the treatment of rabies and chronic Hepatitis B, with potential market acceptance once available.

Furthermore, Brenda Wu discussed the company’s financial performance, noting a decrease in revenue due to COVID-related disruptions affecting manufacturing operations. YS Biopharma remains focused on managing expenses prudently and improving bottom-line performance for fiscal year 2025, with a commitment to generating long-term success and shareholder value.

In conclusion, YS Biopharma’s executives expressed confidence in the company’s strategic initiatives, product pipeline, and future growth prospects. The call concluded with a Q&A session, where analysts and investors had the opportunity to inquire about the company’s performance and future outlook.